[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3674 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 3674
To authorize United States participation in the Davos Alzheimer's
Collaborative.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 3, 2025
Mr. Bera (for himself, Mr. Fitzpatrick, and Mrs. Kim) introduced the
following bill; which was referred to the Committee on Foreign Affairs
_______________________________________________________________________
A BILL
To authorize United States participation in the Davos Alzheimer's
Collaborative.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Global Alzheimer's Initiative Now
Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Alzheimer's disease and dementia currently afflicts
nearly 60 million people across the globe, a number that is
projected to jump to more than 150 million by 2050.
(2) There are now more global cases of Alzheimer's disease
and dementia than cancer and HIV combined, with 39 million
diagnosed cases of HIV/AIDS and 20 million cases of cancer in
2022.
(3) The pace of populations aging will challenge countries'
sovereign funds and health and social safety systems.
(4) By 2050, the world's population of people aged 60 years
and older will double to 1.6 billion and reach a proportion of
22 percent of the world's population. While the number of
persons aged 80 or older is expected to triple by 2050.
(5) The old-age dependency ratio, expressing the relative
size of the older population compared with the working-age
population, is projected to more than double by 2075 in the
majority of the world. Rising dependency ratios will result in
increasing pressures on old-age support systems, with fewer
people of working age for each older person.
(6) The prevalence of Alzheimer's disease and dementia is
growing most rapidly in low- and middle-income countries, which
comprise more than 70 percent of the world's Alzheimer's
disease and dementia cases.
(7) Every year, Alzheimer's disease and dementia costs the
global economy more than $1.3 trillion and this is doubling
every decade.
(8) By 2050, the number of Americans living with
Alzheimer's disease and dementia is expected to reach 12.7
million, bringing the total cost to nearly $1 trillion each
year, with minority populations in the United States
disproportionately impacted by these trends.
(9) International Alzheimer's research across all races and
ethnicities directly benefits minority populations in the
United States.
(10) Women are disproportionately affected by Alzheimer's
disease and dementia, both directly and indirectly. Women
experience higher disability-adjusted life years and mortality
due to Alzheimer's disease and dementia, but also provide 70
percent of care hours for people living with Alzheimer's
disease and dementia.
(11) The Davos Alzheimer's Collaborative (DAC) is a public-
private-patient venture, launched in 2021, that is transforming
Alzheimer's disease and dementia research, prevention, and care
in low-income, middle-income, and high-income settings
globally.
(12) DAC seeks to raise and deploy over $700 million over 6
years to accelerate innovation in drug development and
transform the way healthcare systems prevent, diagnose, and
treat Alzheimer's disease and dementia for all people in all
places.
(13) In 2023, DAC supported 19 healthcare systems in 12
countries, including the United States.
(14) The United States Government has traditionally been
the largest funder of global health programs, with
approximately $12 billion in funding in fiscal year 2024 for
programs that cover the full range of global health challenges.
(15) The United States Government has been a lead funder of
multilateral health initiatives, such as Gavi, the Vaccine
Alliance, the Global Fund to Fight AIDS, TB and Malaria, the
Coalition for Epidemic Preparedness Innovations, and the
International AIDS Vaccine Initiative.
SEC. 3. STATEMENT OF POLICY.
It shall be the policy of the United States--
(1) to lead global cooperative efforts to combat
Alzheimer's disease and dementia, including in countries with
low-income economies and countries with middle-income economies
(as such terms are defined by the World Bank) that represent
the majority of future cases; and
(2) to lead multilateral health initiatives, including the
Davos Alzheimer's Collaborative--
(A) to develop diagnostics and treatments for
diverse populations in the United States and across the
globe;
(B) to promote international development
cooperation; and
(C) to provide substantial leverage and burden
sharing for United States investments.
SEC. 4. AUTHORIZATION FOR UNITED STATES PARTICIPATION IN THE DAVOS
ALZHEIMER'S COLLABORATIVE.
(a) In General.--The United States is hereby authorized to
participate in, and contribute to, the Davos Alzheimer's Collaborative
(DAC) in order to advance international efforts to prevent, diagnose,
and treat Alzheimer's disease and dementia.
(b) Designee.--
(1) In general.--The President is authorized to designate
an employee of the relevant Federal department or agency
providing the majority of United States contributions to DAC to
serve on the Advisory Council of DAC and, if nominated, on the
Board of Directors of DAC, as a representative of the United
States.
(2) Qualifications.--The individual to be designated
pursuant to paragraph (1) should demonstrate knowledge and
experience in the fields of development and public health.
(3) Cooperation.--In carrying out this section, the
individual designated pursuant to paragraph (1) shall
coordinate with the USAID Administrator, the Secretary of
State, and the Secretary of Health and Human Services to
promote alignment, as appropriate, between DAC and United
States global health and Alzheimer's disease and dementia
research and development programs.
(c) United States Contributions.--
(1) In general.--Amounts authorized to be appropriated and
made available to carry out chapters 1 and 10 of part I and
chapter 4 of part II of the Foreign Assistance Act of 1961 (22
U.S.C. 2151 et seq.) are authorized to be made available for
United States contributions to DAC.
(2) Matching requirement.--Amounts made available under
paragraph (1) may be obligated and expended only to the extent
that DAC secures funding from sources other than the United
States. At any time during fiscal years 2026 through 2030, no
United States contribution to DAC may cause the total amount of
United States Government contributions to DAC to exceed 33
percent of the total amount of funds contributed to the DAC
from all sources.
(d) Report.--Not later than 180 days after the date of the
enactment of this Act, and on an annual basis thereafter, the President
shall submit to the appropriate congressional committees a report that
includes the following:
(1) A description of any planned financial contributions
from the United States Government to DAC.
(2) The manner and extent to which the United States will
participate in the governance of DAC.
(3) A summary of private and governmental contributions to
DAC.
(4) A description of how participation in DAC supports
relevant United States Government strategies and programs to
combat Alzheimer's disease and dementia and to promote global
health.
(e) Definition.--In subsection (d), the term ``appropriate
congressional committees'' means--
(1) the Committee on Foreign Affairs and Committee on
Appropriations of the House of Representatives; and
(2) the Committee on Foreign Relations and the Committee on
Appropriations of the Senate.
<all>